Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: Small molecules, big hopes

Journal of Clinical Oncology

Volumn 20, Issue 9, 2002, Pages 2217-2219

  Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG INDUCED DISEASE; EDITORIAL; ENZYME INHIBITION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH;

EID: 0036570107     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.9.2217     Document Type: Editorial

References (24)

1. Untangling the ErbB signalling network
2. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
3. The ErbB signaling network: Receptor heterodimerization in development and cancer
4. Epidermal growth factor-related peptides and their receptors in human malignancies
5. Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
6. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A 431 epidermoid carcinoma cells
7. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
8. Humanization of an anti-p185HER2 antibody for human cancer therapy
9. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
10. Concurrent administration of anti-HER-2 monoclonal antibody and first-line chemotherapy for HER2-overexpresing metastatic breast cancer: A phase III. Multinational, randomized, controlled trial
11. The EGF receptor family as targets for cancer therapy
12. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
13. Tyrosine kinase inhibition: An approach to drug development
14. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
15. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
16. Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 in skin from cancer patients: Histopathological and molecular consequences of receptor inhibition
17. Continuous administration of ZD1839, a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
18. NCIC CTG IND. 122: A two-part phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839
19. Final results from a phase I intermittent dose escalation trial of SZ839 in Japanese patients with various solid tumors
20. Initial results from a phase II trial of ZD1839 ('Iressa') as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1)
21. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
22. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
23. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
24. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma